

# Liverpool City Region: The UK Capital of Vaccine Discovery, Development and Manufacture

Offering an unrivalled collaborative ecosystem of expertise and facilities for every stage of vaccine development and production.

INVEST  
LIVERPOOL  
ADVANCING THE CITY REGION

**The Liverpool City Region has long been a location of excellence in health and life sciences, where world leading research and development aligns with global pharmaceutical manufacturers.**

The City Region has now formally been recognised by the Department for International Trade (DIT) as a location for vaccine discovery, development and manufacture and will be actively showcasing this opportunity to international investors over the coming months and years. Its credentials as a compelling location for vaccine development and manufacturing, spanning R&D, clinical trials, manufacturing and digital infrastructure will be formally launched in April 2022.

Drawing on the best of research, workforce, innovation and digital infrastructure, companies will be able to develop and validate new vaccines and vaccine technologies that will improve the quality of life of people globally. This is an

opportunity to access world class disease and vaccine research, a flexible vaccine manufacturing ecosystem and a dynamic supply chain and logistics network.

The Liverpool City Region has been key to the success in the vaccine innovation and manufacturing of the COVID-19 vaccine due to its established vaccine, biotech and wider life sciences ecosystem. Companies who invest in the City Region can become part of the Regions wider life sciences clusters. A strong health ecosystem offers companies a launchpad into the vaccine industry, from accelerating R&D to product development, access to expertise and regulators, alongside a wide network of NHS trusts, all in close geographical proximity.

## GROWTH FORECAST

The designation of the Liverpool City Region as a location for Vaccine Development by the DIT couldn't be more timely with the global vaccines market size expected to reach £53 billion by 2028, registering a CAGR of 7.3% over the forecast period (2021 – 2028). Major factors driving this growth are rising prevalence of infectious diseases, increasing government funding for vaccine production, and growing emphasis on immunisation.

## RESEARCH AND EXPERTISE

A critical element of the City Region's offer is the pioneering cluster of technical expertise at the Liverpool School of Tropical Medicine (LSTM) and the University of Liverpool (UoL) to develop new vaccines and vaccine technology.

## KEY FACTS

The UK Centre for Tropical & Infectious Diseases with £2 billion of collaborative R&D each year between business, Government, Universities, LSTM, iiCON and others.

A pioneering Civic Data Cooperative providing unique access to population health records for Clinical Trials

Europe's largest concentration of biomanufacturing with the know how to manufacture, fill and finish vaccines in bulk with Astra Zeneca, Seqirus, Bristol Myers Squibb, TriRx & Pharmaron

UKRI's National Centre for Digital Innovation at Sci-Tech Daresbury with AI and Big Data expertise to accelerate biomedical research and discovery

The National Pandemic Institute based at the heart of the Liverpool Knowledge Quarter in The Spine - the world's healthiest building

UK leading Veterinary and Zoonosis Research Centre for the study of animal originated pandemics

The Royal College of Physicians Northern HQ  
114,000 Health & Life Science employees to tap into



Liverpool John Moores University is home to The Centre for Natural Product Discovery, investigating several key aspects of natural products and their pharmaceutical prospects. **The Infection Innovation Consortium (iiCON)** is a leading global centre for infectious disease R&D bringing together industry, academia, and the NHS in a collaborative effort. The Liverpool City Region is also home to the world's first end-to-end response to pandemics through the global Pandemic Institute which has been set up to accelerate response to current and future pandemics, unifying intelligence and generating scientific excellence.

Potential investors will join innovative leaders in biopharma, biotech and vaccines, such as **Astra Zeneca, Seqirus, Bristol Myers Squibb, Pharmaron, TriRx, Teva** and many others. They can accelerate discovery through data, data analytics and powerful computing with the help of key assets such as LSTM, Hartree Centre and the Centre for Genomic Research.

To support digital manufacturing in vaccines, investors will reduce risk and cost by accessing a £15m funded programme aimed at accelerating the implementation of innovative physical and digital manufacturing technologies at the **Digital Manufacturing Accelerator**.

## KEY INVESTMENT LOCATIONS

The Liverpool City Region is part of the Liverpool-Manchester life sciences corridor, which is one of the UK's top biomedical clusters. At the heart of this is the **Liverpool Knowledge Quarter** in the City Centre - home to the Universities, NHS Trusts and research establishments. Biopharma manufacturing takes place across the City Region, with a concentration in South Liverpool. This is supported by other key innovation assets in the City Region including **Sci-Tech Daresbury, the home of UKRI, STFC and the National Centre for Digital Innovation, and The Heath**, a multi-occupancy business and science park in Halton.

The City Region is served by Liverpool and Manchester airports covering **200+ global destinations**. London is just 2 hours away by high speed rail. The Port of Liverpool provides deep water port with more services to and from the US than any other UK port.

Liverpool City Region was awarded Freeport status in March 2021 which provides **significant customs advantages for importers and exporters, alongside capital and other financial incentives** for vaccine manufacturers.

# COME & SEE US AT THE LIVERPOOL PAVILION C19.A

FOR MORE INFORMATION AND  
GREAT OPPORTUNITIES IN LIVERPOOL CITY REGION  
CONTACT [Alice.Lamb@growthplatform.org](mailto:Alice.Lamb@growthplatform.org)  
OR VISIT

[investliverpool.com](http://investliverpool.com)

ARUP

AVISON  
YOUNG

BDP.

Brabners  
we make the difference

Castle  
Green

gleeds

growth  
platform

ION<sup>o</sup>

Liverpool  
BID Company

Liverpool  
City Council

LOVELL

MORGAN  
SINDALL  
CONSTRUCTION

Peel L&P  
REALISING POSSIBILITY

Ryder

Steven A Hunt & Associates

Sutcliffe  
CELEBRATING 35 YEARS

urbansplash

WSP

LIVERPOOL  
CITY REGION  
COMBINED AUTHORITY

METRO MAYOR  
LIVERPOOL CITY REGION

LIVERPOOL  
PLACE  
PARTNERSHIP  
ADVANCING THE CITY REGION

GROUP TO SUPPORT  
INVEST  
IN  
GREAT  
LIVERPOOL CITY REGION

ADVANCING THE CITY REGION